An Observational Study of Dosage Patterns in Routine Clinical Practice in Patients With Rheumatoid Arthritis (ACT-LIFE)

Inclusion Criteria: * Adult patients, \>/= 18 years of age * Moderate to severe rheumatoid arthritis (RA) of at least 6 months duration * Non-responder or intolerant to at least one DMARD or TNF inhibitor treatment * Initiated on treatment with RoActemra according to Summary of Product Characteristics (SPC) indications Exclusion Criteria: * History of autoimmune disease or of any joint inflammatory disease other than RA * Pregnant or lactating women * Patients who have started RoActemra treatment in a clinical trial or for compassionate use * Treatment with any investigational drug in the previous 4 weeks (or at least 5 times the half-life of the drug)